Jake Micallef, PhD, chief scientific officer, VolitionRX, discusses the science of the NuQ biomarker assay as a detection tool for early-stage prostate cancer.
Jake Micallef, PhD
Advertisement
Articles by Jake Micallef, PhD
Jake Micallef, PhD, chief scientific officer, VolitionRX, discusses a study that examined the efficacy of the NuQ biomarker assay as a detection tool for early-stage prostate cancer.
Advertisement
Latest Updated Articles
Dr. Micallef on NuQ Blood Tests in Prostate CancerOctober 4th 2016
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC
3
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
4
Dr Eads on Early Data for CDH17-Directed CAR T-Cell Therapy in R/R GI Cancers
5